<DOC>
	<DOCNO>NCT02765490</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( proportion subject SVR12 ) , safety , tolerability pharmacokinetics 8- 6-week treatment regimen AL-335 , odalasvir ( ODV ) simeprevir ( SMV ) chronic HCV genotype 1 , 2 , 4 , 5 6 infected subject without cirrhosis .</brief_summary>
	<brief_title>Efficacy Safety Combinations AL-335 , Odalasvir ( ODV ) Simeprevir ( SMV ) Treatment Chronic Hepatitis C Infection</brief_title>
	<detailed_description>This Phase 2b multicenter study . The study include screen period maximum 6 week , treatment period 6 8 week 24-weeks post-treatment follow-up period . The total study duration subject 36 38 week . This study investigate 3 direct-acting antiviral agent ( DAA ) combination AL-335 ( HCV NS5B inhibitor ) , odalasvir ( ODV ) ( second generation HCV NS5A inhibitor ) simeprevir ( SMV ) ( HCV NS3A4 protease inhibitor ) . The result study enable selection treatment duration develop .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Individuals chronic hepatitis C virus ( HCV ) genotype 1 , 2 , 4 , 5 6 infection Documented treatment naive experience prior regimen consist Interferon ( IFN ) +/Ribavirin ( RBV ) regimen without achieve sustained viral response Absence cirrhosis Screening laboratory value within defined threshold Must use specific contraceptive method female childbearing potential sexually active male Coinfection human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) Prior exposure HCV directacting antiviral agent ( DAA ) , either combination pegylated interferon ( PegIFN ) IFNfree Current prior history clinical hepatic decompensation History clinically significant illness medical disorder include cardiovascular condition may interfere individual 's treatment , assessment compliance protocol Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>AL-335</keyword>
	<keyword>Odalasvir</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>ODV</keyword>
	<keyword>SMV</keyword>
	<keyword>ACH-3102</keyword>
	<keyword>ACH-0143102</keyword>
	<keyword>TMC435</keyword>
</DOC>